Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 182   

Articles published

PFE 29.11 +0.51 (1.78%)
price chart
US court upholds patents on Pfizer's cancer drug
(Reuters) - A U.S. district court ruled in favor of Pfizer Inc in a patent lawsuit it filed against Mylan Inc alleging patent infringement on its cancer drug, Sutent, Pfizer said.
Related articles »  
Pfizer Approves $11B Stock Repurchase Plan
Pfizer Inc. is the world's second-largest drugmaker, and its products include the vaccine Prevnar and pain and fibromyalgia treatment Lyrica.
Pfizer (PFE) $11 Billion Stock Repurchase Plan May End AstraZeneca (AZN) Bid
NEW YORK (TheStreet) -- Shares of Pfizer Inc (PFE) are climbing, up 1.68% to $29.08 in midday trading, after the U.S. drug maker announced late yesterday that it will continue buying back stock, deflating expectations that it will make a new bid to buy ...
Pfizer Stock Buyback Plan Just Too Large to Ignore � It Is on Viagra  24/7 Wall St.
Pfizer Approves $11B Stock Buyback; Reduces Hopes for AstraZeneca Bid  ValueWalk
Related articles »  
Pfizer Announces $11 Billion Share Buyback Program
Pfizer Inc. (PFE) announced yesterday, that the company plans to buy back shares worth $11 billion, deflating investors' expectations that another bid for AstraZeneca Plc ADR (AZN) might be on its way.
Can This 1 Breast Cancer Drug Turn Pfizer Inc. Into a Growth Stock?
Big Pharma is undergoing a radical face-lift due to the avalanche of top-selling drugs losing patent protection. The consequences of the aptly named "patent cliff" have been widespread and immense in scope.
Pfizer Announces It Will Buy Back $11 Billion in Shares
Pfizer Inc. (PFE) announced today it will buy $11 billion of its shares after walking away from a deal to acquire AstraZeneca Plc earlier this year.
Will Pfizer (PFE) Disappoint This Earnings Season?
Pfizer Inc. (PFE - Analyst Report) is scheduled to report third-quarter 2014 results before the opening bell on Oct 28. Last quarter, the company delivered a positive earnings surprise of 3.57%.
Will Pfizer (PFE) Disappoint This Earnings Season? - Analyst Blog  Nasdaq
Related articles »  
Pfizer Announces Share Buyback, Shares Pop Up
Pfizer Inc. (NYSE: PFE) announced a large $11 billion share repurchase program Thursday night, which is addition to the $1.3 billion remaining in the existing repurchase program.
Should Pfizer Inc. Buy Actavis plc?
Earlier this year, a media circus erupted over Pfizer's reported interest in AstraZeneca (NYSE: AZN ) . The deal would have exceeded $100 billion and created a company roughly the same size as Johnson & Johnson. AstraZeneca brass, however, felt the ...
Pfizer Inc. May Be Interested In Buying Actavis plc [REPORT]  ValueWalk
Pfizer Inc. Is Kicking The Tires At Actavis PLC  Benzinga
Related articles »  
Pfizer Inc. (PFE): Why You Should Sell the Stock [AstraZeneca plc (ADR)]
buyers and sellers Lawrence Meyers: Pfizer Inc. (NYSE:PFE) is the country's largest prescription drug maker, has strong free cash flow, lots of cash, the third-highest dividend yield among the 30 Dow stocks, is attractively valued compared to its peer ...
Multiple Contraction Can Hit Pfizer (PFE)  Seeking Alpha (registration)
Related articles »